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Understanding the mechanism of HIV-1 latency is crucial to eradication of the viral reservoir in HIV-1-
infected individuals. However, the role of histone methyltransferase (HMT) G9a-like protein (GLP) in
HIV-1 latency is still unclear. In the present work, we established four clonal cell lines containing HIV-1
vector. We found that the integration sites of most clonal cell lines favored active gene regions. However,
we also observed hypomethylation of CpG of HIV 5′LTR in all four clonal cell lines. Additionally, 5′-deoxy-
5′-methylthioadenosine (MTA), a broad-spectrum histone methyltransferase inhibitor, was used to
examine the role of histone methylation in HIV-1 latency. MTA was found to decrease the level of
H3K9 dimethylation, causing reactivation of latent HIV-1 in C11 cells. GLP knockdown by small
interfering RNA clearly induced HIV-1 LTR expression. Results suggest that GLP may play a signiﬁcant
role in the maintenance of HIV-1 latency by catalyzing dimethylation of H3K9.
& 2013 Elsevier Inc. All rights reserved.Introduction
Highly active antiretroviral therapy (HAART) can suppress HIV-
1 replication and cripple viral production to the point where viral
levels become undetectable in HIV-1-infected individuals (Chun
et al., 1999; Gulick et al., 1997; Hammer et al., 1997; Perelson et al.,
1997). Despite the great advances that have been made in clinical
antiretroviral therapy, interruption of HAART treatment is still
closely associated with the recovery of HIV-1 replication and
resumption of disease progression. This is because of the viral
reservoir that HIV-1 can form in the human body (Chun et al.,
2000; Finzi et al., 1997; Wong et al., 1997; Zhang et al., 2000). This
reservoir consists of latently infected resting memory CD4þ T
lymphocytes into whose genomes HIV-1 proviruses have
integrated (Loetscher et al., 1999; Stevenson, 2003). This latent
HIV-1 reservoir can exist for long periods of time and so become a
major obstacle to the eradication of HIV in HAART-treated patients.
In latently infected cells, HIV-1 gene expression and viral
production are inhibited after integration. Integration is a crucial
step in the viral infection of CD4þ T cells and one of the ways in
which the virus avoids attack from the host immune system (Colin
and Van Lint, 2009; Engelman et al., 1995; Englund et al., 1995;
Lassen et al., 2004; Sakai et al., 1993). Because HIV DNA can
integrate into the genome of the host cell, it is probable thatll rights reserved.integration can take place in chromatin environments beneﬁcial to
latency (Trono et al., 2010). Some investigations of resting CD4þ T
cells puriﬁed from infected patients on HAART have suggested that
HIV-1 integration acts in a non-random manner in vivo, preferring
the intronic regions of active genes (Colin and Van Lint, 2009; Han
et al., 2004; Wang et al., 2007). This may be because a transcrip-
tional gene named LEDGF/p75 can induce HIV-1 DNA into the
region of actively transcribed genes after interacting directly with
viral integrase (Cherepanov et al., 2003; Lewinski et al., 2006;
Meehan et al., 2009; Schröder et al., 2002; Vandegraaff et al.,
2006). Other studies on the Jurkat cell model have reported that
integration sites have many alphoid repeats rich in heterochro-
matin (Jordan et al., 2001; Jordan et al., 2003; Lenasi et al., 2008).
Elucidating the characteristics of the integration may help us more
clearly understand the mechanisms of HIV-1 latency.
After HIV-1 integration into host genome, chromatin modiﬁca-
tions in viral promoter of HIV-1 long terminal repeat (LTR) become
involved in transcriptional regulations, including CpG methylation
and histone methylation (Bednarik et al., 1987; Bednarik et al.,
1990; Coiras et al., 2009; Gutekunst et al., 1993; Marban et al.,
2007). One study on Jurkat clonal cell lines transfected by HIV-1
derived vector and primary resting memory T cells infected with
HIV-1 showed that CpG methylation levels are universally low.
Even after reactivation of latent HIV-1, these CpG islands retain
hypomethylation (Pion et al., 2003). However, CpG methylation of
HIV-1 5′LTR has been found to be selective and is considered an
important epigenetic control in the maintenance of HIV-1 latency
(Blazkova et al., 2009; Ishida et al., 2006). Observations made on
Fig. 1. Sorting of HIV-1 latently infected cells from GFP-negative cells. Because the
GFP-negative population were composed of uninfected cells and cells containing
transcriptional silenced proviruses, we treated GFP-negative cells with TNF-α at
10 ng/ml, TSA (50 nM, 100 nM, and 200 mM), PMA at 10 ng/ml, PHA at 5 μg/ml, and
1 μM lonomycin for 48 h to activate silenced HIV-1 and sorted out GFP-positive
cells by FACS analysis.
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with HIV-1 indicate that MBD2, a member of the methyl-CpG
binding domain family of proteins, can specially bind methylated
CpG islands and lead to gene silencing by recruitment of tran-
scriptional repressors including the nucleosome remodeling and
histone deacetylation (NuRD) complex (Bird and Wolffe, 1999;
Kauder et al., 2009; Wade, 2001; Zhang et al., 1999). In conclusion,
more analysis is required to conﬁrm the association between HIV-
1 latency and CpG methylation.
Histone methylation has also been associated with transcrip-
tional regulation. It is considered more labile than DNA methyla-
tion (Jones and Baylin, 2007; Kelly et al., 2010; Shi, 2007). Histone
methylation has distinct effects on transcriptional controls
depending on the speciﬁc residues and the pattern of methylation
(Spannhoff et al., 2009). For example, methylation of histone H3
lysine-4 and arginine-17 is commonly associated with activation of
transcription, but methylation of histone H3 lysine-9 and lysine-27
generally leads to inactivation (Huang et al., 2006; Martin and
Zhang, 2005; Spannhoff et al., 2009; Volkel and Angrand, 2007).
Because H3K9 methylation is considered responsible for gene
silencing, some histone methyltransferases (HMTs) that catalyze
H3K9 methylation have been investigated (du Chene et al., 2007;
Imai et al., 2010). Methyltransferases other than Su39H1 and G9a,
have been identiﬁed. These include Suv39H2, GLP (G9a-like
protein)/EHMT1, and SETDB1. These H3K9 HMTs all contain a
common SET-domain, which acts as the catalytic unit (Dillon et al.,
2005; Ogawa et al., 2002; Rea et al., 2000; Schultz et al., 2002;
Tachibana et al., 2001; Yang et al., 2003). GLP, a G9a-related
mammalian H3K9 speciﬁc methyltransferase has been found to
be involved in gene repression (Levy et al., 2010; Tachibana et al.,
2008). However, the role of GLP in HIV-1 latency remains to be
clariﬁed.
The mechanism underlying HIV latency is not absolutely clear.
We established an in vitro model of HIV-1 latency. On the latency
model consisting of four clonal cell lines, we performed a series of
experiments, including analyses of HIV-1 integration sites and
assessments of CpG and H3K9 methylation in HIV 5′LTR to
elucidate the mechanism of HIV-1 latency in our in vitro model
and identify potential targets for complete eradication of latent
HIV-1.Results
Establishment of an in vitro HIV latency model
Plasmid NL43-EGFP was derived from pNL4-3. It is a HIV-1
constructor imported EGFP-encoding gene in a nef open reading
frame. It was here mutated into Env and Vpr genes. We used
pNL43-EGFP and pVSVG to co-transfect 293 T cells for 72 h and
analyzed the relative number of GFPþ cells using FACS analysis.
We used viruses at an m.o.i of 0.1 to infect Jurkat T cells. We
separated GFP-negative cells using FACS after 72 h infection.
Because the GFP-negative population was composed of uninfected
cells and cells containing transcriptional silenced proviruses, we
treated GFP-negative cells with TSA, PMA, TNF-α, PHA, and
lonomycin for 48 h to activate silenced HIV-1 and sorted out
GFP-positive cells using FACS (Fig. 1). These GFP-positive cells
were cultured as a monoclonal cell line for 4 weeks. Several
impure clonal cell lines were discarded, and four clonal cell lines
were selected individually for further analyses.
Location of HIV-1 integration site from latently infected cells
Because each clonal cell line showed nonproductive HIV-1
replication and low, unequal levels of basal transcription, wecloned and indentiﬁed the integration sites of HIV-1 from four
clonal cell lines using an inverse PCR strategy (Fig. 2A). Genomic
DNA was isolated from latently infected cells, digested with the
restriction enzyme PstI, which recognizes a six-base site in gag
gene of HIV and ligates into a self-loop under dilute conditions.
The circularized DNA was used as a template in inverse PCR and
the PCR products were visible on agarose gel (Fig. 2B). Bands were
isolated, cloned, and sequenced.
A total of four distinct clonal cell lines were used to assay the
integration site. Sequences of four unique integration sites were
identiﬁed and analyzed in a BLAST search of GenBank and the
UCSC Bioinformatics Human Genome database. Sequences ﬂank-
ing the 5′LTR of HIV-1 were considered authentic if they showed at
least a 99% match to the human genomic sequence. We then
examined the distribution of integration sites and found the
integration sites of C1, C3, and C11 to be located in introns of
gene regions but those in C13 were downstream of a transcrip-
tional unit. As characterized in Table 1, HIV-1 probably preferred
to integrate in gene-rich regions. This is consistent with previous
in vivo studies (Han et al., 2004).Hypomethylation of the HIV-1 5′LTR in all four clonal cell lines
To determine the possible relationship between latency and
HIV promoter methylation, ﬁve latently infected Jurkat clonal cell
lines C1, C3, C11, and C13, each containing single proviral copy,
were used to investigate HIV 5′LTR cytosine methylation.
The methylation level was dependent on bisulﬁte sequencing.
After bisulﬁte conversion, the cytosine of CpG did not change, but
the cytosine outside CpG was converted to uracil, which is
recognized as thymine in PCR ampliﬁcation. Sequencing showed
that low CpG methylation levels in 5′LTR of these latency models
(3.7±2.6% in C1, 6.2±2.7% C3, 1.2±1.2% C11, 2.5±1.6% C13) (mean
±standard error) (Fig. 3). Another analysis was performed to
evaluate the methylation of each CpG site in the 5′LTR.
No evidence indicated that CpG methylation was associated
with HIV-1 promoter silencing. Some mechanisms other than CpG
methylation in the 5′LTR may contribute to HIV-1 latency.
Fig. 2. HIV integration sites are detected in four latently infected cell lines by inverse PCR. (A) Diagram of inverse PCR. Brieﬂy, DNA puriﬁed from latency cell lines was
digested with PstI, the digested DNA was ligated by T4 ligase and proviral-host DNA junctions were ampliﬁed with two couples of primers under a nested reaction.
(B) Products of inverse PCR from four clonal cell lines were visible in agarose gels. Each band meant a unique integration event. Control reactions carried out either human
genome without HIV infection or no template.
Table 1
Characteristics of HIV-1 integration sites in Jurkat clonal cell lines.
Clonal cell line Conjunctional sequencea Chromosome location Host nt. at the junctionb Gene Integration locus Gene description
C1 ATGCCTGGAA 8q24.3 145153859 SHARPIN Intron SHANK-associated RH domain interactor
C3 AAGGCTGGAA 16p13.3 366460 AXIN1 Intron Axin 1
C11 GAGATTGGAA 16p13.3 2306831 RNPS1 Intron RNA binding protein S1
C13 AAAGGTGGAA 19q13.33 48261159 LOC729626 Intron hypothetical protein
The characteristics of HIV-1 integration sites were analyzed by using Genbank and UCSC database. Sequences ﬂanking to 5′LTR of HIV-1 were considered to be authentic as
they showed at least 99% match to human genomic sequence by BLAST search of GenBank.
a Junction between Human genomic sequence and 5′LTR (ﬁrst ﬁve bases).
b Nucleotide number at integration site.
Fig. 3. CpG methylation proﬁles of 5′LTR in HIV-1 from four Jurkat clonal cell lines. (A) Distributions of CpG dinucleotides in 5′LTR of latent HIV-1 LTR-driven retroviral vector
pNL4-3 are shown as open circles. Genomic DNA from latency cell lines was converted by bisulﬁte treatment and subsequently was used to amply. (B) Different level of
methylation in HIV-1 5′LTR in Jurkat clonal cell lines C1, C3, C11, and C13. Analyses of nine molecules are shown by QUMA online software. Only sequences with at least 98%
conversion of cytosines outside CpG dinucleotides were calculated. Levels of CpG methylation are indicated as a mean±standard error for each clonal cell line.
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C11
MTA is competitive with the SAM cofactor, which can provide
methyl groups for histone methlytransferase. In this way, it plays
an important role in inhibiting methlytransferase activity.
The presence of hypomethylation in CpG islands in vitro latency
cell lines might indicate that some other mechanisms, such as
histone methylation, are involved in HIV-1 latency. Four clonal cell
lines were seeded in 96-well plates at 4×105 cells/ml and treated
with MTA under a concentration gradient (0, 1 μM, 10 μM, 100 μM,
1000 μM) incubated at 37 °C with 5% CO2 for 48 h. As indicated by
FACS analysis, after MTA treatment lasting 48 h, the number of
GFP-positive cells increased obviously in C11 but C1, C3, and C13
showed no signiﬁcant differences from untreated controls (Fig. 4).In this way, MTA was shown to act as a histone methyltransferase
inhibitor. It can apparently induce HIV-1 transcription to reactivate
latent HIV in cell line C11.
Dimethylation of H3K9 leads to HIV latency in C11
MTA is a broad-spectrum histone methyltransferase inhibitor
(Diehl et al., 2007). It can down-regulate gene expression by
inhibiting some histone methyltransferase such as MLL and set1
due to methylation of H3K4 (Huang et al., 2006; Diehl et al., 2007).
Methylation at different residues has distinct effects on gene
expression. For example, methylation at H3K4, H3K36, and
H3K79 is associated with gene activation, and methylation at
H3K9, H3K27, and H4K20 is associated with gene silencing
(Spannhoff et al., 2009). Here, we found MTA treatment increased
Fig. 4. MTA treatment induces HIV-1 transcription in latent cell line C11. (A) After latent cell lines were treated with or without 1mM MTA for 48 h, GFP-positive cells were
analyzed by FACS (FACS Calibur, BD Science) in four clonal cell lines. GFP-positive cells were increased 5.5-fold after 1mM MTA for 48 h in C11. Data was shown as mean
±standard error by three independent experiments. (B) Percentage of GFP-positive cells after 1mMMTA treatment in C11 by FACS analysis. Latent HIV-1 harbored in C11 was
reactivated at the ratio of 13.1% after 1mM MTA treatment for 48 h.
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between latent HIV-1 and MTA indicated the presence of a path-
way involving histone methylation due to the HIV-1 latency.
To demonstrate whether histone methylation was associated with
HIV-1 latency in C11, a ChIP assay was performed to measure the
level of H3K9 me2 and me3 in the LTR promoter of HIV-1. First,
C11 were incubated with 1mM MTA for 24 h, immunoprecipitated
DNA fragments were obtained using antibodies against H3K9 me2
and H3K9 me3. These fragments were subjected to real-time
quantitative PCR analysis. The level of H3K9 me2 was shown to
be down-regulated by approximately 2.27-fold after MTA treat-
ment in C11 cells. The level of H3K9 me3 showed no obvious
change (Fig. 5A).GLP knockdown up-regulates the transcriptional activation of HIV-1
LTR
Because GLP was reported to be involved in the dimethylation
of H3K9, an assay on endogenous GLP knock-down was performed
(Levy et al., 2010). HEK 293 cells were planted and co-transfected
with HIV-1 LTR-luc and either GLP-speciﬁc siRNA or scramble
siRNA. After 48 h incubation, cells were harvested and subjected to
luciferase activity according to the manufacture's protocol.
Luciferase assay showed that GLP knockdown increased the
transcription of HIV-1 LTR over that of cells exposed to scramble
siRNA (2.1-fold change). TNF-α treatment was found to promote
HIV-1 LTR expression (2.3-fold change compared to control siRNA)
(Fig. 6). This experiment indicates that GLP is involved in silencing
the expression of HIV-1 LTR.Discussion
Although HAART can reduce viral load in plasma and improve
patient quality of life, persistence of latent reservoir becomes an
obstacle to prohibit antiretroviral drugs from eliminating HIV-1
completely. For this reason, understanding the mechanism of HIV-
1 latency is considered crucial in our present study.
To establish the HIV-1 latency model, we used an HIV-1-
derived vector to infect Jurkat T cells. This produced latently
infected cells containing a single copy of HIV-1. Studies on
in vitro models of HIV latency have been reported previously.
These models include U1 and ACH2, which exhibit low levels of
basal transcription, despite mutations in Tat (U1) and TAR (ACH2)
(Folks et al., 1986, 1987). HIV latency has also been reported in
Jurkat T cells harboring HIV provirus with deletion of NF-κB
(Antoni et al., 1994). Although these cell lines have served as
classical models in studies on HIV-1 latency, the mutations that
they carry may raise concerns about whether they can hold up a
mirror to HIV-1 latency in vivo (Yang, 2011). Recently, an in vitro
HIV latency model was developed in Jurkat T cells infected with
Tat-driven vector (Jordan et al., 2001, 2003). In this present study,
we used pNL4-3-EGFP, which was reconstructed from pNL4-3 by
introducing in gene encoding enhanced green ﬂuorescent protein
and mutating in Vpr and Env, to infect Jurkat T cells. We ﬁnally
obtained four latently infected cell lines.
In these latent cells, HIV-1 DNA integrates into the host genome
and exhibits low basal transcription. Integration causes a stable,
latent state that allows the virus to evade the immune system and
antiretroviral drugs. Because integration sites have been shown to
play a signiﬁcant role in HIV-1 latency, several studies have
suggested that integration favors in active transcriptional gene
Fig. 5. The level of H3K9 me2 on 5′LTR of HIV-1 is decreased after MTA treatment. (A) As described, ChIP assay was performed after treating C11 either with or without 1mM
MTA for 24 h. Recruitments of H3K9 me2 and H3K9 me3 on 5′LTR of HIV-1 were measured by real-time quantitative PCR. Normal mouse IgG was used as a negative control.
Data are determined by three independent experiments. (B) 20 μl Products of real-time quantitative PCR were visible in agarose gels.
Fig. 6. GLP knockdown up-regulates the transcriptional activation of HIV-1 LTR.
293 cells were co-transfected with 160ng HIV-1 LTR-luc and 100 nM siRNAs (GLP
siRNA or control siRNA) using Lipofectamine 2000 (Invitrogen). After 24 h transfec-
tion, Cells were either treated or untreated with 10 ng/ml TNF-α for additional 24 h.
Cells were ﬁnally harvested after 48 h transfection and subjected to luciferase
activity assay. Results were shown as fold change (mean value±standard error).
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infected with retroviral vector (Han et al., 2004; Brady et al., 2009).
However, analyses of integration sites in a Jurkat T cell model show
that integration distributes in or near the alphoid repeats found in
heterochromatin in most latent cell lines (Jordan et al., 2001). Incontrast, analysis of our small sample set indicated that three out
of four integration sites were located in active gene regions
(Table 1), which is consistent with other in vitro studies
(Lewinski et al., 2006; Schröder et al., 2002). Our conclusion is
probably limited by the small sample size. According to previous
reports, LEDGF/p75 protein is associated with HIV-1 integration
into active transcriptional genes and this protein can vary in
expression depending on different cell types (Brady et al., 2009;
Shun et al., 2007), this may explain its preference for the
integration site.
After the integration of HIV-1 DNA into the host chromatin,
proviral expression is largely governed by host cellular factors. LTR
promoter is the driver of HIV-1 gene expression, including a
number of binding sites essential to the regulation of transcrip-
tional activity (Calman et al., 1988; Parrott et al., 1991; Sune and
Garcia-Blanco, 1995). In this way, epigenetic modiﬁcations of the
HIV-1 5′LTR region have been involved in studies into the
mechanism by which HIV-1 latency is established. DNA methyla-
tion has been shown to be associated with inactivation of HIV LTR
(Bednarik et al., 1987, 1990). In our latent cell lines, we analyzed
CpG methylation of HIV-1 5′LTR and observed hypomethylation in
CpG of HIV 5′LTR in four Jurkat clonal cell lines. These CpG
methylation levels varied from 1.2% to 6.2%. The phenomenon
observed in our study is consistent with the ﬁndings of studies
performed in other Jurkat clonal cells and on primary resting
memory T lymphocytes infected with retroviral vectors (Blazkova
et al., 2009; Pion et al., 2003). Hypermethylation of CpG of HIV-1
5′LTR is observable in latently infected cells selected after two-step
reactivation. This has also been reported in long-term-HIV-1-
infected aviremic individuals but not in viremic patients
(Blazkova et al., 2009). These ﬁndings suggest that methylation
of CpG of HIV-1 5′LTR is probably accompanied by continuous
development of HIV-1 latency. The observation made in ACH-2
cells demonstrates the existence of 5′LTR-selective methylation
(Ishida et al., 2006). Overall, our work suggests that CpG methyla-
tion levels of 5′LTR in HIV-1 are usually low. No 5′LTR-selective
methylation was observed in our in vitro model of HIV-1 latency.
Because hypomethylation was observed in HIV-1 5′LTR, we
speculated that the mechanism of DNA methylation might not be
correlated with initial establishment of HIV-1 latency in our latent
cell lines. Previous studies showed that histone H3K9 methylation
has a deep inﬂuence on regulation of transcription and establish-
ment of HIV-1 latency (du Chene et al., 2007; Imai et al., 2010;
Kubicek et al., 2007; Kelly et al., 2010; Seligson et al., 2005). We
used MTA, a broad-spectrum histone methyltransferase inhibitor,
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methylation. With 1mM MTA treatment, the ratios of GFP-
positive cells were analyzed by FACS after 48 h. Latent HIV-1 in
cell line C11 was reactivated at the ratio of 13.1% by MTA compared
to 2.5% without MTA, but no obvious reactivation was observed in
other clonal cell lines. This suggested that histone methylation
plays a considerable role in HIV-1 latency. To demonstrate this, we
performed a ChIP assay with anti-H3K9 me2 and anti-H3K9 me3
antibodies. The precipitated DNA segments were subjected to real-
time quantiﬁcation PCR. The results showed that level of dimethy-
lation of H3K9 was reduced (2.27-fold change) after MTA treat-
ment. The ChIP assay also conﬁrmed that dimethylation of H3K9
was associated with HIV-1 latency in clonal cell line C11.
Although HIV-1 latency has been shown to be dependent on
H3K9 me2 in C11, no similar results were observed under MTA
treatment in other latent cell lines. Histone acetylation was also
found to be involved in HIV-1 latency, though some studies have
also shown it to be less effective than histone methylation (Colin
and Van Lint, 2009; du Chene et al., 2007). We used a HDAC
inhibitor (trichostatin A, TSA) to reactivate our latent cell lines at
100 nM. Finally, partial latent HIV-1 was reactivated in these clonal
cell lines in the presence of obvious cytotoxicity (data not shown).
The distinct roles of histone methylation in different latent cell
lines could be explained by a study of computational prediction,
This would show whether epigenetic modiﬁcations are associated
with diverse HIV-1 integration sites (Wang et al., 2007).
Some HMTs have been found to participate in the catalysis of
H3K9 methylation. Studies show that SuvH1 and G9a can silence
genes by increasing levels of H3K9 me3,and H3K9 me2 (du Chene
et al., 2007; Imai et al., 2010). Another HMT GLP is also an
important epigenetic marker of gene repression. Previous studies
have reported that GLP knockdown can dramatically reduce the
activity of H3K9 me2 and activate silenced genes (Link et al., 2009;
Tachibana et al., 2005). Here, our work shows that HIV-1 LTR
expression was signiﬁcantly induced after GLP knockdown. The
observations indicate that HMT GLP has been involved in the
maintenance of HIV-1 latency.Conclusion
Curing AIDS has been a major goal for many years, ever since the
disease was discovered. HAART can slow the progression of the
disease, but it has limitations, many of which revolve around the
existence of the HIV-1 reservoir. Studies show that epigenetic mod-
iﬁcations, including histone acetylation and methylation, are closely
associated with HIV-1 latency. Although HMT SuvH1 and G9a have
been found to be recruited in latent HIV-1, other HMTs involved in
HIV-1 latency are still poorly understood. In summary, analyses carried
on our in vitro model of HIV-1 latency suggest that H3K9 dimethyla-
tion, which is catalyzed by HMT GLP, may play a more signiﬁcant role
in the maintenance of HIV-1 latency than CpG methylation does.
These ﬁndings present novel evidence that HMT GLP takes part in
HIV-1 latency and may be a suitable target for therapy in HIV-1-
infected individuals. Considering that the process of HIV latency is
subjected to multiple forms of regulation, clariﬁcation of the molecular
mechanism of HIV-1 latency requires further investigation in the hope
of providing an effective platform for eradication of latent HIV-1.Materials and methods
Cell culture and drug treatment
293 T cells, 293 cells, and TZM-bl cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Gibco) medium supplementedwith 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/
ml streptomycin (Invitrogen), and were incubated at 37 °C with 5%
CO2. Jurkat T cells were cultivated in the same condition except that
DMEM medium was replaced by RPMI 1640 medium (Gibco).
5′-deoxy-5′-methylthioadenosine (MTA), Trichostatin A (TSA),
Phorbol 12-Myristate-13-Acetate (PMA), Tumor Necrosis Factor-α
(TNF-α), phytohaemagglutinin (PHA), and lonomycin were dis-
solved in anhydrous dimethyl sulfoxide (DMSO) (Sigma-Aldrich).
Cells were treated with these reagents for further analyses in
different time phases.
Plasmids
HIV-1 vector plasmid NL4-3-EGFP was kindly provided by
Dr. Jianqing Xu (Institute of Bioscience, Fudan University, Shang-
hai, China). HIV-1 LTR-luciferase (LTR-luc) plasmid was con-
structed as described (du Chene et al., 2007).
Virus production and cell infection
For viral production, 2×105 293T cells were transfected with
15 μg pNL43-EGFP and 7.5 μg pVSVG. Supernatants containing
viral particles were harvested after 72 h and centrifugated to
remove scraps under 3000 rpm for 5 min. Jurkat T cells were
infected with viral suspension at an m.o.i of 0.1 after centrifuging
under 1200g for 2 h at room temperature as described previously
(Chun et al., 1998; Hauber, 2008). Cells were washed by 1×PBS
twice and added 2ml fresh RPMI 1640 medium containing 10%
FBS. Cells were cultured at 37 °C with 5% CO2 for 72 h and
differentiated GFP negative cells from all by ﬂow cytometry
analysis (FACS-Aria machine, BD Science). GFP-negative cells were
separated and stimulated with TSA, PMA, TNF-α, PHA, and lono-
mycin to sort out GFP-positive cells that are the latently infected
cells. These latently infected cells were cultured selectively and
ﬁnally four clonal cell lines were obtained and labeled as Clone 1
(C1), Clone 3 (C3), Clone 11 (C11), and Clone 13 (C13).
Detection of HIV integration site
Inverse PCR procedure was used to detect HIV integration site
in our established in vitro model of HIV latency. In brief, genomic
DNA extracted from latent cell lines was digested with PstI, the
digested DNA was ligated by T4 ligase and provirus-host DNA
junctions were ampliﬁed with two couples of primers under a
nested reaction as previously described (Han et al., 2004). Bands
on agarose gels were puriﬁed, cloned and sequenced. The Human
sequence ﬂanking to 5′LTR of HIV-1 was identiﬁed by BLAST search
of GenBank or UCSC Bioinformatics Human Genome database.
Cytosine methylation analysis of HIV-1 5′LTR
The samples of total genomic DNA from four latent cell lines
were extracted and proceeded to analyze according to the proce-
dure provided by EZ DNA Methylation-Gold kit (Zymo Research).
As described by Pion et al. (2003), modiﬁed DNA was ampliﬁed
by PCR application using two pairs of primers. PCR was performed
by 30 cycles at 95 °C for 60 s, 58 °C for 120 s, and 72 °C for 60 s.
PCR products were separated, eluted, cloned in the pMD18-T
Vector (Takara), and sequenced ﬁnally. Sequences were obtained
from at least nine PCR clones after excluding clones with lower
than 95% conversion of cytosines outside CpGs. Ultimate results of
sequencing were analyzed by accessing to Quantiﬁcation Tool for
Methylation Analysis (QUMA) (Kumaki et al., 2008; Kauder et al.,
2009 ).
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ChIP experiments were performed according to the protocol
provided by EZ-ChIP™ Chromatin Immunoprecipitation Kit (Milli-
pore). C11 was incubated either with or without MTA (1 mM) for
24 h before ChIP assays. Cells were cross-linked in 1% formaldehyde
for 10 min at room temperature and quenched with 0.125 M Glycine
for 5 min. After lysis, chromatin was sheared by sonicator for a total
of 12 min (10 s on, 10 s off) on ice to obtain DNA fragments at the
length of 200–1000 bp. 10% of total sheared chromatin DNAwas used
as input DNA. Other sheared chromatin was incubated with anti-
bodies against H3K9me2, H3K9me3 (Abcam), and normal mouse IgG
(Millipore) for a negative control. The immunoprecipitated DNA was
analyzed by a real-time PCR (ABI Prism 7900 Real-Time PCR System)
at 30 cycles with Taq Mastermix (Invitrogen) using primers for 5′LTR
of HIV-1 (forward: 5′-TAGCAGTGGCGCCCGAACAGG-3′, reverse: 5′-
GCCTCTTGCCGTGCGCGCTTC-3′).
Transient transfection and RNA interference
Small interference RNAs (siRNAs) against GLP and scramble
siRNA as negative control were synthesized by Invitrogen.
The target sequences are as follows: GLP (5′-GCACAAACAGCGUG-
GUCAATT-3′) and control (5′-UUCUCCGAACGUGUC ACGUTT-3′).
293 cells were co-transfected with 160 ng HIV-1 LTR-luc and
100 nM siRNAs using Lipofectamine 2000 (Invitrogen). After 24 h
transfection, Cells were either treated or untreated with 10 ng/ml
TNF-α for additional 24 h. Cells were ﬁnally harvested after 48 h
transfection and subjected to luciferase activity assay according to
Luciferase Assay System™ (Promega).Acknowledgments
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